<DOC>
	<DOCNO>NCT02716207</DOCNO>
	<brief_summary>The maximum tolerate dose locally advanced unresectable pancreatic tumor treat CyberKnife SBRT evaluate .</brief_summary>
	<brief_title>Phase ǀ Study Pancreatic Cancer Treated CyberKnife</brief_title>
	<detailed_description>Pancreatic cancer fourth-leading cause cancer-related death world . It characterize metastatic spread local failure seldom detect earlier stage . For locally advanced stage pancreatic cancer , complete surgical removal hard achieve . Stereotactic body radiotherapy ( SBRT ) CyberKnife unresectable pancreatic tumor relatively new treatment option make available significant improvement diagnostic image radiation delivery technique . Different conventional radiotherapy , radiation dose deliver few fraction higher fractional dos SBRT . Gurka ( 1 ) report 14 patient receive SBRT prescription dose 25 Gy five fraction biologically equivalent dos ( BED ) α/β=10 correspondence 37.5Gy . Grade 1 2 gastrointestinal toxicity ( grade 3 4 radiation-related toxicity ) observe two week treatment . Two patient partial response , 12 patient stable disease . In previous dose escalation study , single fraction to15 Gy , 20 Gy , 25 Gy equivalent BED10 37.5 Gy , 60 Gy , 87.5 Gy respectively recommend Koong AC ( 2 ) team . Even though local control rate 100 % , follow short sample size 15 patient relatively small . Moreover , late toxicity investigate . And single fraction scheme , high late gastrointestinal ( GI ) toxicity report ( 2,3,4 ) . In meanwhile , investigator ( 5 , 6 ) South Korea examine Dmax 35Gy 38Gy 3 fraction ( BED10 75.8Gy 86.1Gy ) SBRT correlate 5 % 10 % rate grade 3 gastroduodenal toxicity abdominal malignant tumor , respectively . Chuong ( 7 ) use 5 fraction potentially decrease risk late normal tissue injury compare 1 3 fraction commonly use institution . Assuming α/β=3 , BED3 deliver normal tissue study ( use mean 36.4 Gy 5 fraction high dose PTV ) 125 Gy , low mean BED3 series , correspond value Boston Stanford 153.7 Gy ( mean , 32.96 Gy 3 fraction ) 233.3 Gy ( mean , 25Gy 1 fraction ) , respectively ( 8 , 9 ) . And relatively low incidence grade ≥3 late adverse effect ( 5.3 % VS 9 % ) observe . Since treatment modality dose still exploratory stage , propose conduct Phase I study determine maximum tolerate dose CyberKnife SBRT dose escalation treatment locally advance pancreatic tumor base 5 fraction treatment regimen . A prescription dose 35-47.5 Gy five fraction choose , equivalent traditional dose 2 Gy 25-39 fraction BED10 . And assume safe effective dose unresectable pancreatic cancer patient . Study Procedure : CyberKnife SBRT body fixation ( vacuum-bag ) use immobilize body , arm legs . - Patients undergo plain CT well enhance pancreatic parenchymal CT radiation treatment plan target delineation . - SBRT deliver CyberKnife Synchrony Respiratory Tracking system . The tumor track implanted fiducial marker Fiducial Tracking System . Treatment deliver 5 fraction within 1 2 week discretion investigator . - A body fixation ( vacuum-bag ) use immobilize body , arm ( arm along body ) legs .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Unresectable pancreatic adenocarcinoma unsuitable/unwilling resection prove biopsy . A life expectancy &gt; 3months Eastern Cooperative Oncology Group ( ECOG ) status ≤2 Tumor size &lt; 5 cm Tumor location : Head pancreas Patients must able undergo contrast enhance CT plan Absolute neutrophil count ( ANC ) ≥ 1.5 ×109 cells/L Leukocyte count≥ 3.5 ×109cells/L Platelets ≥ 70×109cells/L Hemoglobin ≥ 8.0 g/dl Albumin &gt; 2.5 g/dL Total bilirubin &lt; 3 mg/dL Creatinine &lt; 2.0 mg/dL INR &lt; 2 ( 0.91.1 ) Aspartate transaminase ( AST ) &lt; 2.5 × Upper Limit Normal ( ULN ) ( 064U/L ) Alanine aminotransferase ( ALT ) &lt; 2.5 × ULN ( 064U/L ) Both men woman member race ethnic group eligible study Ability research subject authorize legal representative understand willingness sign write informed consent document Tumor marker lab test do less 1 week recruitment Prior surgery , chemotherapy radiation pancreatic tumor Prior radiotherapy upper abdomen , evidence metastatic disease nodal distant metastasis abdomen CT chest CT FDG PETCT Contraindication receive radiotherapy Distance gross tumor volume ( GTV ) ( lesion ) luminal structure ( include liver , stomach , duodenum , small large bowel ) is＜5 mm Women pregnant Participation another clinical treatment trial study Patients fiducial implantation possible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Stereotactic Body Radiotherapy ( SBRT )</keyword>
	<keyword>CyberKnife</keyword>
	<keyword>Dose Escalation</keyword>
</DOC>